CHT101 / Nanjing Calmhome Cell & Gene Engineering Institute - LARVOL DELTA

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Universal CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

COURAGE: A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P1 trial • Cutaneous T-cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

Metastases • New P1 trial • Oncology • Solid Tumor

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Zhejiang University

New P1 trial • Cervical Cancer • Genito-urinary Cancer • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD70